Trial Profile
Phase II study of nab-paclitaxel for pretreated NSCLC
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Dec 2017 Status changed from recruiting to discontinued.
- 09 Jul 2014 New trial record